Discovery of Baicalein as a Novel Ubiquitin-Specific Protease 21 Inhibitor for the Treatment of Hepatocellular Carcinoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Ubiquitin-specific protease 21 (USP21) inhibition shows promise for hepatocellular carcinoma (HCC) treatment. Baicalein, a novel USP21 inhibitor, suppresses HCC growth by destabilizing HIF-1α and enhancing anti-tumor immunity.
Area Of Science
- Oncology
- Molecular Biology
- Drug Discovery
Background
- Ubiquitin-specific protease 21 (USP21) is overexpressed in hepatocellular carcinoma (HCC), linked to poor patient prognosis.
- USP21 inhibition is a potential therapeutic strategy for HCC.
Purpose Of The Study
- Identify novel USP21 inhibitors for HCC treatment.
- Elucidate the molecular mechanisms of USP21 inhibitors in HCC.
Main Methods
- Structure-guided drug discovery, enzymatic assays, and bio-layer interferometry.
- Functional assays (proliferation, migration, apoptosis) and in vivo efficacy studies.
- Molecular dynamics simulations and binding free energy calculations.
Main Results
- Baicalein and Hypericin identified as USP21 inhibitors.
- Baicalein suppressed HCC proliferation, migration, and colony formation, inducing apoptosis.
- Baicalein disrupted USP21-HIF-1α interaction, promoting HIF-1α degradation and enhancing anti-tumor immunity.
Conclusions
- Baicalein is a dual-functional USP21 inhibitor with therapeutic potential for HCC.
- The identified binding motif provides a blueprint for future USP21-targeted drug design.
- USP21 inhibition represents a promising strategy for HCC treatment.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
